RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 Promising Agent Identified as Specific Antidote to Factor Xa Inhibition
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 21
SP 17
OP 17
DO 10.1177/155989771421010
UL http://mdc.sagepub.com/content/14/21/17.abstract
AB Antidotes to Factor Xa inhibitors are under development and should enhance the safety of the new oral anticoagulant (NOAC) agents. Reversal of a NOAC is necessary in certain circumstances, such as a spontaneous or provoked hemorrhage (rate of 10% to 20% in Phase 3 trials), an emergency or invasive procedure that requires the rapid reversal of anticoagulation, or serious bleeding in a critical organ.